{"page_content": "PURSUING THE HIGHEST ETHICAL STANDARDSALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT    |  23\nTraining\nOur employees receive mandatory quarterly compliance training, periodic \nwritten reminders on compliance matters and are offered a variety of other \nresources and trainings to encourage diversity, equity and inclusion, anti-\nharassment and compliance with laws  . In addition, the Senior Leadership \nTeam undergoes annual training by external counsel on compliance matters  .\nReporting Resources and Non-Retaliation\nIf someone at Allogene has a good faith complaint regarding a possible \nviolation of law or policy, we expect them to report that complaint \npromptly  . We offer a 24/7 whistleblower hotline managed by a third party \nto allow for anonymous reports  . Third parties, including consultants and \nvendors, may also make a good faith complaint  . Employees are \nencouraged to report non-compliance without fear of any form of retaliation  . \nWe will take prompt disciplinary action against any employee who \nretaliates, up to and including termination of employment  .\nOur Board has designated our General Counsel as our Compliance Officer, \nwho is required to follow certain procedures upon the receipt of any report \nalleging violation of company policies  . \nEmployees who do not feel comfortable speaking with our Compliance \nOfficer can contact our Chief Financial Officer, Chief Executive Officer or \nthe chair of the Board of Directors\u2019 Audit Committee  . Clinical Trials \nAllogene is a clinical-stage company and we do not currently \ncommercialize or market any prescription biopharmaceutical products  .  \nWe design and conduct our clinical trials with high standards per \nInternational Conference on Harmonisation of technical requirements for \nregistration of pharmaceuticals for human use and Good Clinical Practice \n(ICH-GCP)  . We follow the ICH-GCP standards, which are consistent \nwith global ethical standards that have their origin in the World Medical \nAssociation\u2019s Declaration of Helsinki, to ensure that ethical and scientific \nqualities are maintained throughout our trials to generate results that are \nreliable and valid  .\nPrior to commencing any clinical trial, we must meet strict rules set forth \nby the U  .S . Food and Drug Administration (FDA), including submitting an \nInvestigational New Drug (IND) application for clearance by the FDA  . In \naddition, an independent Institutional Review Board (IRB) for each clinical \ntrial site must review and approve the plan for any clinical trial before it \ncommences at that site  . Upon trial initiation, we take responsibility for \nensuring that the clinical trial is conducted in accordance with an \ninvestigational plan and protocol that is in conformity with all regulatory \nrequirements and approvals  . ", "metadata": {"source": "NASDAQ_ALLO_2022.pdf", "page": 24, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}